<DOC>
	<DOCNO>NCT00042874</DOCNO>
	<brief_summary>Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . This phase I trial study side effect best dose combination chemotherapy treat patient locally advance metastatic solid tumor .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose flavopiridol ( alvocidib ) administer irinotecan hydrochloride , fluorouracil , leucovorin calcium patient locally advance metastatic solid tumor . II . Determine clinical pharmacokinetics fluorouracil administer regimen patient . III . Determine , preliminarily , therapeutic activity regimen patients.Correlate role p21 Drg1 apoptosis treatment response patient receive regimen . OUTLINE : This dose-escalation study alvocidib fluorouracil ( 5-FU ) . Patients receive irinotecan hydrochloride IV 90 minute follow 5 hour later leucovorin calcium IV 2 hour alvocidib IV 1 hour immediately follow 5-FU IV continuously 48 hour begin day 1 week 1 , 3 , 5 . Courses repeat every 6 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos alvocidib 5-FU maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Ten additional patient treat MTD . PROJECTED ACCRUAL : A total 27-77 patient accrue study within 11-38 month .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Histologically cytologically confirm locally advanced metastatic solid tumor Refractory standard therapy standard therapy Preference give colorectal cancer , upper gastrointestinal cancer , neuroendocrine tumor Evaluable disease No CNS metastases primary CNS malignancy Performance status Karnofsky 60100 % WBC least 3,500/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin great 1.5 mg/dL AST ALT great 2.5 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) Creatinine great 1.5 mg/dL No history cardiac arrhythmia No congestive heart failure No myocardial infarction within past 6 month No prior grade 3 4 diarrhea secondary irinotecan , despite optimal antidiarrheal prophylaxis HIV negative No serious uncontrolled infection No medical condition reason would preclude study participation Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 2 month study participation At least 2 week since prior immunotherapy No 2 prior chemotherapy regimen unless evidence significant myelotoxicity determine primary investigator At least 2 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) Prior irinotecan fluorouracil allow At least 2 week since prior radiotherapy Recovered prior therapy No concurrent investigational medication No concurrent vitamin , antioxidant , herbal preparation supplement except single daily multivitamin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>